This study involves adults with **chronic kidney disease (CKD)**, a long-term condition where the kidneys don't work as well as they should. Participants must be 18 or older and have specific kidney function levels. The study tests a new combination of medicines: **vicadrostat** and **empagliflozin**. Participants are split into two groups randomly. One group takes both medicines daily for 3 months, while the other starts with a **placebo** (a pill with no medicine) and empagliflozin for 1.5 months, followed by both medicines for another 1.5 months. The study lasts about 4.5 months with multiple visits to the study site for kidney check-ups and health monitoring. **Key Points:** - **Duration:** The study lasts around 4.5 months. - **Visits:** Participants need to visit the study site multiple times. - **Eligibility:** Must not have used certain medications recently and meet specific health criteria. Doctors will monitor kidney function and check for any side effects. Participants will learn if starting both medicines together or one after the other works better for CKD.